SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-033825
Filing Date
2023-09-27
Accepted
2023-09-27 06:15:20
Documents
16
Period of Report
2023-09-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 51016
2 ex10-1.htm EX-10.1 68549
3 ex99-1.htm EX-99.1 15462
4 ex99-1_001.jpg GRAPHIC 4237
  Complete submission text file 0001493152-23-033825.txt   379763

Data Files

Seq Description Document Type Size
5 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lixt-20230926.xsd EX-101.SCH 3785
6 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lixt-20230926_def.xml EX-101.DEF 26651
7 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lixt-20230926_lab.xml EX-101.LAB 36785
8 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lixt-20230926_pre.xml EX-101.PRE 25275
10 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5244
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 231281769
SIC: 2834 Pharmaceutical Preparations